Dexlansoprazole: A Review of Analytical Methods for Estimation in Pharmaceutical Formulation

Abstract

Dexlansoprazole was approved by the U.S. Food and Drug Administration (FDA) in 2009. Dexlansoprazole (DSP) is a proton pump inhibitor, it used to treat GERD and ulcer colitis. DSP works by decreasing the volume of acid in the stomach. DSP is an acid-labile medication that may be destroyed in the stomach's acidic pH. A coating technique was used to postpone drug release in the stomach, which can extend pharmacological activity. There have been numerous methods developed so far for quantitative estimation of Dexlansoprazole in bulk and pharmaceutical dosage form. Pharmaceutical analytical methods include UV Visible Spectrophotometry, High Pressure Thin Layer Chromatography, Reversed Phase High Performance Liquid Chromatography and hyphenated techniques like Liquid chromatography- Mass Spectrometry.